Robert P. Byington

18.1k total citations · 5 hit papers
55 papers, 11.9k citations indexed

About

Robert P. Byington is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Robert P. Byington has authored 55 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cardiology and Cardiovascular Medicine, 25 papers in Surgery and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Robert P. Byington's work include Lipoproteins and Cardiovascular Health (21 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Diabetes Treatment and Management (9 papers). Robert P. Byington is often cited by papers focused on Lipoproteins and Cardiovascular Health (21 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers) and Diabetes Treatment and Management (9 papers). Robert P. Byington collaborates with scholars based in United States, Canada and Australia. Robert P. Byington's co-authors include Hertzel C. Gerstein, Michael E. Miller, David C. Goff, John B. Buse, William C. Cushman, Denise G. Simons‐Morton, Saul Genuth, J. Thomas Bigger, Faramarz Ismail‐Beigi and Richard H. Grimm and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Robert P. Byington

55 papers receiving 11.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Intensive Glucose Lowering in Type 2 Diabetes

2008 5.5k citations Hertzel C. Gerstein, Michael E. Miller et al. profile →
Intensive glucose control and macrovascular outcomes in type 2 diabetes

2009 829 citations Robert P. Byington, Hertzel C. Gerstein et al. profile →
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

1994 685 citations Curt D. Furberg, William B. Applegate et al. Circulation profile →
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES

2010 640 citations Hertzel C. Gerstein, Robert P. Byington et al. profile →
Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM

1998 603 citations Robert P. Byington et al. Diabetes Care profile →

Peers

Robert P. Byington

EDM

CCM

SURGE

PRM

Hans‐Henrik Parving Denmark

John Fuller United Kingdom

David C. Wheeler United Kingdom

Gérald Luc France

Hans‐Henrik Parving Denmark

Sander J. Robins United States

Richard W. Nesto United States

H. A. W. Neil United Kingdom

John R. Guyton United States

Olov Wiklund Sweden

Hans‐Henrik Parving Denmark

Robert P. Byington

8.3k ×1.2

EDM

7.8k ×1.9

CCM

2.1k ×0.7

SURGE

1.9k ×1.0

1.4k ×1.2

PRM

Citations per year, relative to Robert P. Byington Robert P. Byington (= 1×) peers Hans‐Henrik Parving

Countries citing papers authored by Robert P. Byington

Since Specialization

Citations

This map shows the geographic impact of Robert P. Byington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert P. Byington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert P. Byington more than expected).

Fields of papers citing papers by Robert P. Byington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert P. Byington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert P. Byington. The network helps show where Robert P. Byington may publish in the future.

Co-authorship network of co-authors of Robert P. Byington

This figure shows the co-authorship network connecting the top 25 collaborators of Robert P. Byington. A scholar is included among the top collaborators of Robert P. Byington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert P. Byington. Robert P. Byington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Isakova, Tamara, Timothy E. Craven, Jungwha Lee, et al.. (2014). Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology. 10(1). 29–38. 20 indexed citations

Elam, Marshall B., Laura Lovato, Robert P. Byington, et al.. (2010). Abstract 19724: Hypertriglyceridemia and Low HDL-C Predicts Fenofibrate Response in The ACCORD-Lipid Trial. Circulation. 122. 2 indexed citations

Riddle, Matthew C., Walter T. Ambrosius, David J. Brillon, et al.. (2010). Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. Diabetes Care. 33(5). 983–990. 292 indexed citations

Goff, David C., Hertzel C. Gerstein, Henry N. Ginsberg, et al.. (2007). Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. The American Journal of Cardiology. 99(12). S4–S20. 180 indexed citations

Byington, Robert P. & Frank M. Sacks. (2004). Lessons learned from the prospective pravastatin pooling project. Current Atherosclerosis Reports. 6(5). 366–374. 2 indexed citations

Hennekens, Charles H., Frank M. Sacks, Andrew Tonkin, et al.. (2004). Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease. Archives of Internal Medicine. 164(1). 40–40. 82 indexed citations

Crouse, John R., Robert P. Byington, & Curt D. Furberg. (1998). HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 138(1). 11–24. 89 indexed citations

Byington, Robert P., et al.. (1998). Lipid lowering therapy in CAD patients at Academic Medical Centers: undertreatment and evidence of a gender gap. Journal of the American College of Cardiology. 31. 186–186. 3 indexed citations

Byington, Robert P., Michael E. Miller, Ward A. Riley, et al.. (1997). Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). The American Journal of Cardiology. 80(8). 1087–1090. 44 indexed citations

10.

Dolecek, Therese A., et al.. (1996). Maximizing recruitment efforts in a drug lipid-lowering trial with dietary intervention to lower LDL cholesterol. Controlled Clinical Trials. 17(1). 33–45. 1 indexed citations

11.

Adams, Harold P., Robert P. Byington, Helena Hoen, Robert J. Dempsey, & Curt D. Furberg. (1995). Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke. Cerebrovascular Diseases. 5(3). 171–177. 22 indexed citations

12.

Crouse, John R., Robert P. Byington, M. Gene Bond, et al.. (1995). Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). The American Journal of Cardiology. 75(7). 455–459. 497 indexed citations

13.

Furberg, Curt D., et al.. (1995). Reduction in coronary events during treatment with pravastatin. The American Journal of Cardiology. 76(9). 60C–63C. 37 indexed citations

14.

Furberg, Curt D., Robert P. Byington, John R. Crouse, & Mark A. Espeland. (1994). Pravastatin, lipids, and major coronary events. The American Journal of Cardiology. 73(15). 1133–1134. 65 indexed citations

15.

Furberg, Curt D., et al.. (1993). Calcium Antagonists and Atherosclerosis The Multicenter Isradipine/Diuretic Atherosclerosis Study. American Journal of Hypertension. 6(3_Pt_2). 24S–29S. 15 indexed citations

16.

Crouse, John R., Robert P. Byington, M. Gene Bond, et al.. (1992). Pravastatin, lipids, and atherosclerosis in the carotid arteries: Design features of a clinical trial with carotid atherosclerosis outcome. Controlled Clinical Trials. 13(6). 495–506. 56 indexed citations

17.

Applegate, William B. & Robert P. Byington. (1991). MIDAS, The Multicenter Isradipine/Diuretic Atherosclerosis Study. American Journal of Hypertension. 4(2_Pt_2). 114S–117S. 8 indexed citations

18.

Peters, Robert W., Robert P. Byington, Allan H. Barker, & Salim Yusuf. (1990). Prognostic value of prolonged ventricular repolarization following myocardial infarction: The BHAT experience. Journal of Clinical Epidemiology. 43(2). 167–172. 83 indexed citations

19.

Friedman, Lawrence M., Robert P. Byington, Robert J. Capone, et al.. (1986). Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. Journal of the American College of Cardiology. 7(1). 1–8. 91 indexed citations

20.

Friedman, Lawrence M. & Robert P. Byington. (1985). ASSESSMENT OF ANGINA PECTORIS AFTER MYOCARDIAL INFARCTION: COMPARISON OF “ROSE QUESTIONNAIRE” WITH PHYSICIAN JUDGMENT IN THE BETA-BLOCKER HEART ATTACK TRIAL. American Journal of Epidemiology. 121(4). 555–562. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact